| Autor: |
Mechulan, A., Prevot, S., Peret, A., Nait-Saidi, L., Miliani, I., Lemann, T., Vaugrenard, T., Houamria, S., Leude-Vaillant, E., Vaillant, A., Cornen, A., Latiere, B., Giacomoni, M.P., Collet, F., Bechet, V., Bouharaoua, A., Dieuzaide, P. |
| Zdroj: |
Archives of Cardiovascular Diseases; Jan2024:Supplement, Vol. 117 Issue 1, pS100-S101, 2p |
| Abstrakt: |
Transvenous pacemaker (PM) implantation is a complication in patients undergoing transcatheter aortic valve implantation (TAVI). Recently, a second-generation of leadless PMs able of atrioventricular (AV) synchronous pacing have been introduced and could be an alternative when ventricular pacing is required after TAVI. Real-world data on Micra AV after TAVI are still lacking. Our aim was to determine 12 months' outcomes in patients with Micra AV leadless PM implantation after TAVI. A total of 20 consecutive patients underwent Micra AV leadless PM implantation after TAVI between November 2020 and June 2021. The main indication for ventricular pacing was high-degree atrioventricular block (55% of patients) and left bundle branch block associated with prolonged HV interval (45% of patients). At 1-year follow-up, mean (SD) ventricular pacing threshold was 0.571 ± 0.22 V at 0.24 ms and ventricular impedance was 534.4 ± 51 W. In patients with ventricular pacing > 90% (n = 4), mean AM-VP was 74.43 ± 11.2%. Pacing threshold at 12-month was significantly higher compared to discharge (P ** = 0.0027). Mean (SD) impedance was 534.4 ± 51 W, which was lower compared to discharge (P *** < 0001). At 1-year follow-up, survival was 80%. Micra AV leadless PM implantation after TAVI is associated with good device performance and 20% mortality at 1 year. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect